EMEA-001435-PIP02-16
Key facts
| Invented name |
Vandaag
|
| Active substance |
Anifrolumab
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0075/2018
|
| PIP number |
EMEA-001435-PIP02-16
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of Systemic Lupus Erythematosus (SLE)
|
| Route(s) of administration |
|
| Contact for public enquiries |
AstraZeneca AB (Sweden)
Tel. +46 8 55327591 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|